4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Charmacy Pharmaceutical Co., Ltd. (2289) operates in the Medical Distribution industry and is headquartered in Shantou, China with about 847 employees. Its market capitalization is roughly CNY 594 million. In the fiscal year ended 2025-12-31, 2289 reported CNY 4.4B in revenue and CNY 46M in net income.
Charmacy Pharmaceutical Co., Ltd. engages in the pharmaceutical distribution business in the People's Republic of China. It distributes western medicines, Chinese patent medicines, healthcare products, and pharmaceutical products to downstream distributors and retail terminals.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | CNY 4.4B | CNY 4.4B | CNY 4.4B | CNY 4.2B | — |
| Gross Profit | CNY 340M | CNY 325M | CNY 293M | CNY 272M | — |
| Operating Income (EBIT) | CNY 149M | CNY 140M | CNY 115M | CNY 100M | — |
| Net Income | CNY 46M | CNY 53M | CNY 51M | CNY 90M | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Dividends Paid | (CNY 80M) | (CNY 64M) | (CNY 76M) | (CNY 28M) | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | CNY 4.0B | CNY 3.5B | CNY 3.2B | CNY 2.9B | — |
| Total Liabilities | CNY 3.3B | CNY 2.8B | CNY 2.6B | CNY 2.3B | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2289 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms